Literature DB >> 15342387

Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression.

Kai Breuhahn1, Sebastian Vreden, Ramsi Haddad, Susanne Beckebaum, Dirk Stippel, Peer Flemming, Tanja Nussbaum, Wolfgang H Caselmann, Brian B Haab, Peter Schirmacher.   

Abstract

Molecular subtyping of human hepatocellular carcinoma (HCC) with potential mechanistic and therapeutic impact has not been achieved thus far. We have analyzed the mRNA expression patterns of 43 different human HCC samples and 3 HCC cell lines in comparison with normal adult liver using high-density cDNA microarrays. Two main groups of HCC, designated group A (65%) and group B (35%), were distinguished based on clustering of the most highly varying genes. Group A HCCs were characterized by induction of a number of interferon (IFN)-regulated genes, whereas group B was characterized mainly by down-regulation of several apoptosis-relevant and IFN-regulated genes. The number of apoptotic tumor cells and tumor-infiltrating lymphocytes was significantly higher in tumors of group A as compared with those of group B. Based on the expression pattern, group B was further subdivided into two subgroups, designated subgroup B1 (6 of 43 tumors, 14%) and subgroup B2 (9 of 43 tumors, 21%). A prominent characteristic of subgroup B1 was high overexpression of insulin-like growth factor (IGF)-II. All tested HCC cell lines expressed equally high concentrations of IGF-II transcripts and co-segregated with group B1 in clustering. IGF-II overexpression and induction of IFN-related genes were mutually exclusive, even when analysis was extended to other cancer expression profile studies. Moreover, IFN-gamma treatment substantially reduced IGF-II expression in HCC cells. In conclusion, cDNA microarray analyses provided subtyping of HCCs that is related to intratumor inflammation and tumor cell apoptosis. This profiling may be of mechanistic and therapeutic impact because IGF-II overexpression has been linked to reduced apoptosis and increased proliferation and may be accessible to therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15342387     DOI: 10.1158/0008-5472.CAN-04-0292

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Subset of Suz12/PRC2 target genes is activated during hepatitis B virus replication and liver carcinogenesis associated with HBV X protein.

Authors:  Leo L Studach; Stephan Menne; Stefano Cairo; Marie Annick Buendia; Ronald L Hullinger; Lydie Lefrançois; Philippe Merle; Ourania M Andrisani
Journal:  Hepatology       Date:  2012-10       Impact factor: 17.425

2.  [Molecular mechanisms of progression in human hepatocarcinogenesis].

Authors:  K Breuhahn
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

3.  Effects of alpha-interferon on insulin-like growth factor-I, insulin-like growth factor-II and insulin-like growth factor binding protein-3 secretion by a human lung cancer cell line in vitro.

Authors:  P Del Monte; C Laurino; M Arvigo; C Palermo; F Minuto; A Barreca
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

4.  Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

Authors:  Derek Y Chiang; Augusto Villanueva; Yujin Hoshida; Judit Peix; Philippa Newell; Beatriz Minguez; Amanda C LeBlanc; Diana J Donovan; Swan N Thung; Manel Solé; Victoria Tovar; Clara Alsinet; Alex H Ramos; Jordi Barretina; Sasan Roayaie; Myron Schwartz; Samuel Waxman; Jordi Bruix; Vincenzo Mazzaferro; Azra H Ligon; Vesna Najfeld; Scott L Friedman; William R Sellers; Matthew Meyerson; Josep M Llovet
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

5.  Epigenetic modulation of insulin-like growth factor-II overexpression by hepatitis B virus X protein in hepatocellular carcinoma.

Authors:  Xu You Liu; Shao Hui Tang; Sheng Lan Wu; Yu Hong Luo; Ming Rong Cao; Hong Ke Zhou; Xiang Wu Jiang; Jian Chang Shu; Cai Qun Bie; Si Min Huang; Zhan Hong Zheng; Fei Gao
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

Review 6.  Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.

Authors:  Yujin Hoshida; Sara Toffanin; Anja Lachenmayer; Augusto Villanueva; Beatriz Minguez; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

7.  [Highly differentiated liver tumors: recent developments and their diagnostic application].

Authors:  P Schirmacher; T Longerich
Journal:  Pathologe       Date:  2009-12       Impact factor: 1.011

8.  Molecular classification of hepatocellular carcinoma: potential therapeutic implications.

Authors:  Nicolas Goossens; Xiaochen Sun; Yujin Hoshida
Journal:  Hepat Oncol       Date:  2015

Review 9.  Molecular targeted therapies in hepatocellular carcinoma.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

10.  Genome-wide differences in hepatitis C- vs alcoholism-associated hepatocellular carcinoma.

Authors:  Celine Derambure; Cedric Coulouarn; Frederique Caillot; Romain Daveau; Martine Hiron; Michel Scotte; Arnaud Francois; Celia Duclos; Odile Goria; Marie Gueudin; Catherine Cavard; Benoit Terris; Maryvonne Daveau; Jean-Philippe Salier
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.